Zevra Therapeutics (NASDAQ:ZVRA) Receives Buy Rating from HC Wainwright

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 152.53% from the stock’s previous close.

Several other equities research analysts have also weighed in on ZVRA. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. Guggenheim set a $21.00 target price on shares of Zevra Therapeutics and gave the stock a “buy” rating in a report on Tuesday, February 4th. Canaccord Genuity Group decreased their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $21.71.

Zevra Therapeutics Trading Down 1.9 %

Zevra Therapeutics stock opened at $7.92 on Thursday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company’s fifty day simple moving average is $7.95 and its 200-day simple moving average is $8.14. The stock has a market cap of $422.74 million, a P/E ratio of -4.02 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The firm had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. As a group, sell-side analysts forecast that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Insider Transactions at Zevra Therapeutics

In related news, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the completion of the sale, the chief executive officer now owns 222,060 shares in the company, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Joshua Schafer sold 10,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the sale, the executive vice president now directly owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. The trade was a 26.26 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 85,773 shares of company stock valued at $674,176. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

A number of large investors have recently bought and sold shares of the business. Vestal Point Capital LP acquired a new position in shares of Zevra Therapeutics during the third quarter worth approximately $3,644,000. Geode Capital Management LLC raised its holdings in Zevra Therapeutics by 14.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after purchasing an additional 129,600 shares during the last quarter. Barclays PLC lifted its stake in shares of Zevra Therapeutics by 292.6% in the 3rd quarter. Barclays PLC now owns 57,599 shares of the company’s stock valued at $399,000 after purchasing an additional 42,926 shares during the period. Propel Bio Management LLC acquired a new position in shares of Zevra Therapeutics during the 3rd quarter worth about $1,248,000. Finally, Simplify Asset Management Inc. acquired a new position in Zevra Therapeutics during the third quarter valued at approximately $833,000. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.